安科生物两药品拟中选集采接续采购，多款创新药研发取得进展

Core Viewpoint - Anke Bio (300009) has made significant progress in drug procurement and innovative drug development, which may positively impact sales volume and market share in the coming years [1][2]. Group 1: Stock Performance - The company announced that its Atosiban injection and Propofol-Tenofovir oral sustained-release formulation are expected to be selected for the national drug procurement agreement, with the procurement cycle planned until December 31, 2028 [1]. Group 2: Product Development Progress - Multiple innovative drug developments have advanced, including HER2-targeted drugs such as HuA21 injection (completed Phase Ib/II enrollment, planning Phase III), AK2024 injection (Phase I clinical), and HK010 bispecific antibody (Phase II first enrollment) [2]. - In the growth hormone sector, AK2017 injection (recombinant human growth hormone-Fc fusion protein) has entered Phase III clinical trials [3]. - The anti-infection drug AK1012 project (interferon α2b inhalation solution) is currently undergoing Phase II/III clinical trials [4]. - The company's affiliate, Bosheng Jianke, has its PA3-17 injection (CD7-CAR-T therapy) included as a breakthrough therapy, currently in critical Phase II clinical trials [4]. - Yuan Song Bio's "recombinant L-IFN adenovirus injection" has progressed to Phase IIa [4]. - The AFN0328 injection (treatment for HPV-related lesions), developed in collaboration with Afana, has completed Phase I clinical trials and is a first-in-class drug [5]. Group 3: Strategic Advancement - The company plans to introduce long-acting growth hormone (representing Weisheng Pharmaceutical products) and long-acting follicle-stimulating hormone (exclusively introducing products from Baoji Pharmaceutical) after Q3 2025 to strengthen its position in pediatric growth and reproductive assistance [6]. - A 3-10 year development strategy is being formulated, focusing on gene-engineered drugs, antibody drugs, and cell therapy sectors [6].